COLUMBIA, Md., Sept. 22 /PRNewswire-FirstCall/ -- The Board of Directors of Martek Biosciences Corporation (Nasdaq: MATK) today announced that it has elected Steve Dubin as President.
"Steve has been key in developing Martek's business over the last eleven years. He has the experience, leadership ability and vision to take Martek to much higher levels of success," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek.
Mr. Dubin has served in a variety of positions with Martek between 1992 and 2000 including CFO, Treasurer, Secretary, General Counsel and Senior VP of Business Development. In 2000, he moved to a part-time position of Senior Advisor - Business Development, a role in which he has continued filling until his current election. Mr. Dubin's previous experience includes working with a variety of technology companies and spending twelve years in various positions at Suburban Bank, now part of Bank of America, including Vice President and Treasurer of its venture capital subsidiary, Suburban Capital Corporation. In this position, he helped lead Martek's initial round of institutional financing in 1986. Since 2000, Mr. Dubin has also co-founded and managed an angel-investing club that funds early stage, high potential businesses.
A Maryland native, Mr. Dubin graduated from the University of Maryland, College Park, where he studied business and accounting. He received his Juris Doctor Degree from the National Law Center at the George Washington University in Washington, D.C. Mr. Dubin is a licensed CPA and a member of the Maryland Bar.
As President of Martek, Mr. Dubin will be responsible for Operations, including the current production expansion, Research and Development, Human Resources and Business Development.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding Martek's business. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.